Organization of a Randomized Clinical Trial for the Prevention of Recurrent Thrombosis in the Antiphospholipid Syndrome: the WAPS Project (Warfarin in Antiphospholipid Syndrome)

  • G. Finazzi
  • R. Marchioli
  • T. Barbui
Conference paper


Antiphospholipid (aPL) antibodies are a heterogeneous family of immunoglobulins directed against different protein-phospholipid complexes [1, 2]. They include lupus anticoagulants (LA) and anticardiolipin antibodies (aCL). The former recognize the (human) prothrombin-phospholipid complex, thereby inhibiting the phospholipid-dependent coagulation reactions [3], whereas the latter is directed towards β2-glycoprotein I (β2-GPI) bound to an anionic lipid surface [4, 5]. aCL can be divided into two groups [6, 7]: aCL type A, which inhibit coagulation reactions by enhancing the binding of β2-GPI to the procoagulant phospholipid surface; and aCL type B, which are devoid of anticoagulant properties. In recent years, the presence of aPL which recognize lipid-bound Protein S and lipid-bound activated Protein C (aPC) has been reported [8–10]. A consistent finding of many studies is the inhibition by aPL of the inactivation of factor Va by aPC in the presence of Protein S. In this way, aPL can interfere with the physiological function of these natural anticoagulants, suggesting a possible, albeit still unproven, mechanism for their association with thrombotic events [11, 12].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Triplett DA (1995) Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 78: 1–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Vermylen J, Arnout J (1992) Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid–protein complexes? J Lab Clin Med 120: 10–12PubMedGoogle Scholar
  3. 3.
    Bevers EM, Galli M, Barbui T et al (1991) Lupus anticoagulant IgG’s ( LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin, Thromb Haemostas 66: 629–632Google Scholar
  4. 4.
    Galli M, Comfurius P, Maassen C et al (1990) Anticardiolipin antibodies ( ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 336: 177–178Google Scholar
  5. 5.
    McNeil HP, Simpson RJ, Chesterman CN et al (1990) Anticardiolipin antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation 132glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87: 4120–4124PubMedCrossRefGoogle Scholar
  6. 6.
    Galli M, Comfurius P, Barbui T et al (1992) Anticoagulant activity of 132-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 68: 297–300PubMedGoogle Scholar
  7. 7.
    Galli M, Finazzi G, Bevers EM et al (1995) Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and ß2-glycoprotein I-dependent antiphospholipid antibodies. Blood 86: 617–623PubMedGoogle Scholar
  8. 8.
    Marciniak E, Romond EH (1989) Impaired catalytic function of activated Protein C: a new in vitro manifestation of lupus anticoagulant. Blood 74: 2426–2432PubMedGoogle Scholar
  9. 9.
    Malia RG, Kitchen S, Greaves M et al (1990) Inhibition of activated protein C and its cofactor S by antiphospholipid antibodies. Br J Haematol 76: 101–110PubMedCrossRefGoogle Scholar
  10. 10.
    Oosting JD, Derksen RHWM, Bobbink WG et al (1983) Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 81: 2618–2625Google Scholar
  11. 11.
    Svensson PJ, Dahlback B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330: 517–522PubMedCrossRefGoogle Scholar
  12. 12.
    de Groot PG, Derksen RHWM (1994) Protein C pathway, antiphospholipid antibodies and thrombosis. Lupus 3: 229–234PubMedCrossRefGoogle Scholar
  13. 13.
    Hughes GRV (1993) The antiphospholipid syndrome: ten years on. Lancet 3: 341–344CrossRefGoogle Scholar
  14. 14.
    Alarcon-Segovia D, Sanchez-Guerrero J (1989) Primary antiphospholipid syndrome. J Rheumatol 16: 482–488PubMedGoogle Scholar
  15. 15.
    Asherson RA, Khamashta MA, Ordi-Ros J et al (1989) The primary antiphospholipid syndrome: major clinical and serologic features. Medicine 68: 366–374PubMedCrossRefGoogle Scholar
  16. 16.
    Vianna JL, Khamashta MA, Qrdi-Ros J et al (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 96: 3–9PubMedCrossRefGoogle Scholar
  17. 17.
    Love PE and Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 112: 682–698PubMedGoogle Scholar
  18. 18.
    Branch WD, Dudley DJ, Mitchell MD et al (1990) IgG fractions from patients with antiphospholipid antibodies cause fetal death in Balb/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 163: 210–216PubMedGoogle Scholar
  19. 19.
    Sthoeger ZM, Tartakovsky B, Bentwich Z (1993) Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. J Clin Immunol 13: 127–138PubMedCrossRefGoogle Scholar
  20. 20.
    Pierangeli SS, Barker JH, Stikovac et al (1994) Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemostas 71: 670–674Google Scholar
  21. 21.
    Ginsburg KS, Liang MH, Newcomer L et al (1992) Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117: 997–1002PubMedGoogle Scholar
  22. 22.
    Nencini P, Baruffi MC, Abbate R et al (1992) Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 23: 189–193PubMedCrossRefGoogle Scholar
  23. 23.
    Levine SR, Brey RL, Joseph CLM et al (1992) Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 23 (Suppl I): 29–32Google Scholar
  24. 24.
    Muir KW, Squire IB, Alwan W et al (1994) Anticardiolipin antibodies in an unselected stroke population. Lancet 344: 452–456PubMedCrossRefGoogle Scholar
  25. 25.
    Hamsten A, Bjorkholm M, Norberg R et al (1986) Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet i: 113–116CrossRefGoogle Scholar
  26. 26.
    Sletnes KE, Smith P, Abedlnoor et al (1992) Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction and nonhaemorrhagic stroke. Lancet 339: 451–453PubMedCrossRefGoogle Scholar
  27. 27.
    Finazzi G, Brancaccio V, Moia M et al (1996) Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A four-year prospective study from the Italian Registry. Am J Med 100: 530–536PubMedCrossRefGoogle Scholar
  28. 28.
    Barbui T, Finazzi G (1994) Clinical trials on antiphospholipid syndrome: what is being done and what is needed? Lupus 3: 303–337PubMedCrossRefGoogle Scholar
  29. 29.
    Derksen RHWM, de Groot PG, Kater L et al (1993) Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 52: 689–692PubMedCrossRefGoogle Scholar
  30. 30.
    Rosove MH, Brewer PMC (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Int Med 117: 303–308PubMedGoogle Scholar
  31. 31.
    Khamashta MA, Cuadrado MJ, Mujic F et al (1995) The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 332: 993–997PubMedCrossRefGoogle Scholar
  32. 32.
    Lockshin MD (1995) Answers to the antiphospholipid-antibody syndrome ? N Engl J Med 332: 1025–1027PubMedCrossRefGoogle Scholar
  33. 33.
    Nasr SZ, Parke AL (1995) Thrombosis in the antiphospholipid syndrome. N Engl J Med 333: 666 (letter)PubMedGoogle Scholar
  34. 34.
    Slivka A, Walz E (1995) Thrombosis in the antiphospholipid syndrome. N Engl J Med 333: 665–666 (letter)PubMedCrossRefGoogle Scholar
  35. 35.
    Ginsberg JS, Wells PS, Brill-Edwards P et al (1995) Antiphospholipid antibodies and venous thromboembolism. Blood 86: 3685–3691PubMedGoogle Scholar
  36. 36.
    Dalen JE, Hirsh J (1992) Third ACCP Consensus Conference on antithrombotic therapy. Chest (Suppl) 102: 303–538Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • G. Finazzi
  • R. Marchioli
  • T. Barbui

There are no affiliations available

Personalised recommendations